Cargando…
Prevention and management of hearing loss in patients receiving ototoxic medications
Following the efforts of patient advocates, the World Health Organization published updated guidelines for management of multidrug-resistant tuberculosis in 2018 that advised against the routine use of ototoxic second-line injectable drugs (amikacin, capreomycin and kanamycin). Although hearing loss...
Autores principales: | Lindeborg, Michael M, Jung, David H, Chan, Dylan K, Mitnick, Carole D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Health Organization
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706352/ https://www.ncbi.nlm.nih.gov/pubmed/36466201 http://dx.doi.org/10.2471/BLT.21.286823 |
Ejemplares similares
-
Communicating with people with hearing loss: COVID-19 and beyond
por: Maru, Devina, et al.
Publicado: (2021) -
Education and health of children with hearing loss: the necessity of signed languages
por: Murray, Joseph J, et al.
Publicado: (2019) -
The need to accelerate access to new drugs for multidrug-resistant tuberculosis
por: Cox, Helen S, et al.
Publicado: (2015) -
Preventing ototoxic hearing loss by inhibiting histone deacetylases
por: Layman, W S, et al.
Publicado: (2015) -
Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss
por: Li, Hui, et al.
Publicado: (2022)